local_hospital

Spitalul Clinic Judetean De Urgenta Cluj

Address
lock Available on a paid plan

Nervous System Diseases

At Spitalul Clinic Judetean De Urgenta Cluj, clinical research is centered on nervous system diseases, with a strong focus on neurological conditions that affect daily function and quality of life. The studies in this area are designed to better understand long-term treatment safety and tolerability, helping to support more reliable care options for patients.

  • Migraine research in children and adolescents, focused on evaluating the long-term safety and tolerability of preventive treatment.
  • Multiple sclerosis studies, including both relapsing and progressive forms, aimed at assessing the safety and tolerability of a potential therapy over time.

This work reflects a practical interest in improving treatment confidence for chronic neurological disorders, while supporting care for both younger patients and adults living with complex neurological conditions.

Site Overview

assignment
6
connected trials
corporate_fare
7
sponsors
science
11
IMPs

Activity Indicator

Last 6 months

2
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
6
Total trials linked
Active
trending_upGrowing+100%
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
5
Sponsors (total)
7
Active sponsors
6

Sponsor Network

Top 6 by active trials.

lock +5 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 442 other sites in Romania

description
Trial volume
6
Outperforms 66% of sites
public
Therapeutic diversity
4areas
Outperforms 82% of sites
groups
Sponsor diversity
7sponsors
Outperforms 78% of sites

Therapeutic Area Benchmark — Romania

Select a therapeutic area to compare against other sites in Romania.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Romania

Market Share

Country: Romania

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Spitalul Clinic Judetean De Urgenta Cluj

lock Showing 1 of 6 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with MigraineAbbVie Deutschland GmbH & Co. KGPhase IIIRecruitingDec 2023

IMP list

lock Showing 1 of 11 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol1Unknown

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.